Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lovastatin + minocycline
- Development stage
- Phase 2
- Lead developer
- Université de Sherbrooke
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of lovastatin (a cholesterol-lowering medication) and minocycline (an antibiotic) that has been studied for the treatment of Fragile X syndrome (FXS). This dual treatment approach appears to work synergistically to improve behavioral symptoms and address neurophysiological abnormalities in Fragile X syndrome, including reducing cortical excitability and restoring inhibitory signaling.
- Other names
- LovaMiX
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)MMP9 (Matrix metalloproteinase-9)MMP12 (Macrophage Metalloelastase)
Beyond the preview
Go deeper on lovastatin + minocycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lovastatin + minocycline.